ClinicalTrials.gov
Cure8 trial brief
Mirikizumab Real World Protocol
Research and clinical trials
Mirikizumab
IL-23 inhibitor
Phase 2 clinical trial
Adult patients
Clinicians
Researchers
Patients On Biologics
Why This Matters
Real-world registries can show how a drug performs outside clinical trials and how patients feel over time; this study aimed to track symptoms for people starting mirikizumab for ulcerative colitis.
Knowing the study was terminated and had a very small planned enrollment is important when judging how useful its data would be.
Who Should Pay Attention
Adults with ulcerative colitis, clinicians prescribing mirikizumab or following patients on biologics, researchers interested in real-world evidence for IL-23 inhibitors, and patient registries/advocacy groups.
Study Snapshot
Story typeClinical Reference
Evidence typeClinical trial
Enrollment6 participants
Study statusTerminated
Source depthTrial registry record
What To Know
This is a terminated observational registry study that planned to collect 1-year patient-reported outcomes (SCCAI) from adults with ulcerative colitis who were starting mirikizumab (Omvoh) as part of routine care.
The study intended to measure clinical response at multiple time points over 52 weeks using the Simple Clinical Colitis Activity Index (SCCAI) via online surveys. Registry status is listed as TERMINATED and planned enrollment was small (6). The record describes inclusion/exclusion criteria and participating US centers.
Because this is a trial registry entry (observational design) and marked TERMINATED, it reports planned study design and outcomes but does not present trial results or analyses. The brief summarizes the registry record rather than any published findings.
If you are tracking mirikizumab use or real-world data collection in UC, note this record documents an attempted prospective patient-reported outcomes registry but does not provide outcome data.
Keep In Mind
This is a clinicaltrials.gov record for an observational study and is marked TERMINATED; the record describes planned methods and outcomes but does not report results. Planned enrollment was 6, so even if completed the dataset would be very small. Mirikizumab (Omvoh) is an IL-23–targeting therapy -- this registry focused on patient-reported SCCAI scores over 52 weeks.
Source Details
Review the original publication for the complete reporting, methods, and context.
Clinical trial
Evidence type derived from source or registry metadata.
PublicationClinicalTrials.gov
SponsorUniversity of North Carolina, Chapel Hill
Trial IDNCT06696014
Study typeObservational
Enrollment6 participants
Indexed viaClinicalTrials.gov
Source typeTrial registry record
PublishedSep 24, 2026, 12:00 AM
Content availableTrial registry record
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis
This trial tests two investigational agents (eltrekibart and mirikizumab) for moderate–severe ulcerative colitis, which may offer additional treatment options if proven safe and effective. It’s relevant to people whose...
LY4268989 (MORF-057) Co-Administered With Mirikizumab in Adults With Moderately to Severely Active Ulcerative Colitis:
This trial tests whether adding an investigational oral agent (LY4268989) to mirikizumab improves remission rates in people with moderately to severely active ulcerative colitis. If successful, it could expand treatment...
Switching to the IL-23 Inhibitor Guselkumab for People With Active IBD Who Previously Used Ustekinumab (SHIFT-IBD)
People with IBD who don’t respond well to ustekinumab may need alternative options. This study will track how patients fare after switching to guselkumab in routine clinical care and report rates of deep remission at one...